(Total Views: 730)
Posted On: 09/03/2019 9:01:10 AM
Post# of 82
Progress!
BRIEF-Bioline RX Says Completed Dose-Escalation Part Of Phase 1/2A Clinical Study For AGI-134
BY Reuters
— 7:13 AM ET 09/03/2019
Sept 3 (Reuters) - BioLine RX Ltd ( BLRX COMPLETED DOSE-ESCALATION PART OF PHASE 1/2A CLINICAL STUDY FOR AGI-134
AGI-134 WAS FOUND TO BE SAFE AND WELL TOLERATED WITH NO DOSE-LIMITING TOXICITIES OBSERVED
* BIOLINE RX LTD ( BLRX ) - MAXIMAL TOLERATED DOSE WAS NOT REACHED AND RECOMMENDED DOSE FOR PART 2 OF STUDY WAS DETERMINED
BIOLINE RX LTD LOOKING FORWARD TO INITIATING PART 2 OF AGI-134 STUDY SHORTLY, WITH INITIAL RESULTS EXPECTED BY YEAR-END 2020
BRIEF-Bioline RX Says Completed Dose-Escalation Part Of Phase 1/2A Clinical Study For AGI-134
BY Reuters
— 7:13 AM ET 09/03/2019
Sept 3 (Reuters) - BioLine RX Ltd ( BLRX COMPLETED DOSE-ESCALATION PART OF PHASE 1/2A CLINICAL STUDY FOR AGI-134
AGI-134 WAS FOUND TO BE SAFE AND WELL TOLERATED WITH NO DOSE-LIMITING TOXICITIES OBSERVED
* BIOLINE RX LTD ( BLRX ) - MAXIMAL TOLERATED DOSE WAS NOT REACHED AND RECOMMENDED DOSE FOR PART 2 OF STUDY WAS DETERMINED
BIOLINE RX LTD LOOKING FORWARD TO INITIATING PART 2 OF AGI-134 STUDY SHORTLY, WITH INITIAL RESULTS EXPECTED BY YEAR-END 2020
(0)
(0)
